UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000047726
Receipt No. R000054416
Scientific Title Investigation of the effects of test-food intakes on gut environment
Date of disclosure of the study information 2022/05/11
Last modified on 2022/05/11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Investigation of the effects of test-food intakes on gut environment
Acronym Investigation of the effects of test-food intakes on gut environment
Scientific Title Investigation of the effects of test-food intakes on gut environment
Scientific Title:Acronym Investigation of the effects of test-food intakes on gut environment
Region
Japan

Condition
Condition Healthy adults
Classification by specialty
Not applicable Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 In order to investigate some kind of effect on gut environment by the test-food ingestion for 4 weeks.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Fecal IgA level
Key secondary outcomes 1. Gut microbiota
2. Gut metabolites
3. Defecation status (the number of days, frequency, quantity, property, color, feeling of incomplete evacuation, abdominal pain, fecal odor)

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 Consumption of the test food (1 g per day) every day for 4 weeks.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
80 years-old >
Gender Male and Female
Key inclusion criteria (1) At informed consent, male/female subjects aged more than or equal to 20, and less than 80 years old.
(2) Subjects who can show understanding of the study procedures and agreement with participating in the study by written informed consent prior to the study.
Key exclusion criteria (1) Subjects who have consumed cellobiose within the last 1 month to the study start, or have a plan to consume it during this study.
(2) Subjects who are regularly consuming foods for specified health uses, foods with function claims, supplements and/or health foods for more than 3 times a week, which would affect the study results.
(3) Subjects who have current medical history/anamnesis of immune-related diseases such as autoimmune diseases or digestive ones.
(4) Pregnant, possibly pregnant, or lactating women.
(5) Subjects who have an allergy to the test food.
(6) Subjects who have been determined ineligible for participation, judging from the principal investigator's opinions.
Target sample size 10

Research contact person
Name of lead principal investigator
1st name Shinnosuke
Middle name
Last name Murakami
Organization Metagen, Inc.
Division name Headquarters
Zip code 997-0052
Address 246-2 Mizukami, Kakuganji, Tsuruoka, Yamagata, Japan
TEL +81-235-64-0330
Email research@metagen.co.jp

Public contact
Name of contact person
1st name Shinnosuke
Middle name
Last name Murakami
Organization Metagen, Inc.
Division name Headquarters
Zip code 997-0052
Address 246-2 Mizukami, Kakuganji, Tsuruoka, Yamagata, Japan
TEL +81-235-64-0330
Homepage URL
Email research@metagen.co.jp

Sponsor
Institute Metagen, Inc.
Institute
Department

Funding Source
Organization KAKUI CO., LTD
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Institutional Review Board of Chiyoda Paramedical Care Clini
Address 2F Daiwa Building, 3-3-10 Nihonbashihongoku-cho, Chuo-ku, Tokyo 103-0021, Japan
Tel +81-3-6225-9005
Email IRB@cpcc.co.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2022 Year 05 Month 11 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Preinitiation
Date of protocol fixation
2022 Year 04 Month 18 Day
Date of IRB
2022 Year 04 Month 15 Day
Anticipated trial start date
2022 Year 05 Month 12 Day
Last follow-up date
2022 Year 06 Month 30 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2022 Year 05 Month 11 Day
Last modified on
2022 Year 05 Month 11 Day


Link to view the page
URL(English) https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054416

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.